Physician profile
James Schultz
NPI 1770814766
$5,075.01
in general payments reported to CMS, 2019-2025
22 companies · $1,511 in 2025
The $1,511 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $946 · 2022: $360 · 2023: $1,192 · 2024: $1,066 · 2025: $1,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,769.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,916.54 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,480.28 | 2021-2025 | |
| Lilly USA, LLC | $524.22 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $262.59 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $200.86 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.77 | 2021-2025 | Jardiance, Synjardy |
| Exact Sciences Corporation | $92.09 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $75.02 | 2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $49.29 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.73 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $41.10 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $36.85 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $34.26 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $33.97 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $29.81 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $28.74 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $20.37 | 2024 | Trintellix |
| Seqirus USA INC | $19.49 | 2024 | Flucelvax, Fluad |
| Xeris Pharmaceuticals, INC. | $18.83 | 2025 | Gvoke Hypopen |
| Medtronic, INC. | $13.64 | 2025 | Intellis Adaptivestim |
| Biohaven Pharmaceuticals, INC. | $13.61 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.95 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.